Clinical Trials and Development - The company is developing REQORSA® Gene Therapy for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC), with a recommended Phase 2 dose of 0.12 mg/kg administered every 21 days[515]. - In the Phase 1 portion of the Acclaim-1 trial, three out of twelve patients experienced prolonged progression-free survival, with one patient maintaining a partial remission for approximately 42 months[515]. - The Acclaim-1 trial has received FDA Fast Track Designation for the combination treatment of REQORSA and Tagrisso in NSCLC patients[516]. - The Phase 2a expansion of the Acclaim-3 trial is expected to enroll approximately 50 patients, with an interim analysis planned after the first 25 patients reach 18 weeks of follow-up[519]. - The Acclaim-2 trial, which involved a combination of REQORSA and Keytruda, has been closed due to slow enrollment and competition for eligible patients[518]. - The Phase 2 expansion portion of the Acclaim-3 trial aims to determine the 18-week progression-free survival rate in patients with extensive stage small cell lung cancer[519]. - The company is collaborating with MD Anderson to identify biomarkers that may predict patient response to REQORSA in lung cancer treatments[514]. Financial Performance - Research and development (R&D) expense decreased by $1,106,726, or 11%, to $9,428,720 for the year ended December 31, 2025, primarily due to the closure of the Acclaim-2 clinical trial and a reduction in R&D staff from 9 to 7 employees[543]. - General and administrative (G&A) expense decreased by $4,545,129, or 43%, to $6,086,899 for the year ended December 31, 2025, mainly due to one-time charges and a significant reduction in share-based compensation[544]. - Net loss for the fiscal year ended December 31, 2025, was $16,228,953, a decrease of $4,882,210, or 23%, compared to a net loss of $21,111,163 for the fiscal year ended December 31, 2024[547]. - As of December 31, 2025, the accumulated deficit was $171,028,396, with no revenue generated from product sales since inception[549]. - Interest income decreased to $26,900 for the year ended December 31, 2025, from $63,574 in 2024, primarily due to lower cash balances in interest-bearing accounts[545]. - Depreciation expense was $0 for the year ended December 31, 2025, compared to $6,693 in 2024, reflecting changes in accounting policies[546]. Capital and Funding - For the year ended December 31, 2025, the company sold 1,602,490 shares of common stock for net proceeds of approximately $10.8 million under the 2023 ATM Facility[551]. - The company entered into a Purchase Agreement with Lincoln Park for an equity line of credit of up to $12.5 million over 24 months, subject to certain conditions[552]. - As of December 31, 2025, the company had $7,830,855 in cash and received net proceeds of approximately $13.3 million through its 2023 ATM Facility after year-end[554]. - The company anticipates needing to raise additional capital to fund ongoing clinical trials, including Acclaim-1 and Acclaim-3, which are currently enrolling[555]. - The company has registered $75 million of shares for sale under the ATM, with approximately $58.6 million remaining unsold as of the report date[553]. - The company expects to fund its operations into the second quarter of 2027 but will require additional fundraising activities by that time[559]. Strategic Considerations - The company plans to retain its oncology clinical development programs while potentially transferring its diabetes clinical development program to a new subsidiary, Convergen Biotech, Inc.[524]. - The company is considering various strategic alternatives to enhance stockholder value, including optimizing clinical and research programs[537]. - The company expects R&D expenses to increase in the future as it advances product candidates through clinical trials and expands research programs[537]. - The company faces uncertainty regarding its ability to maintain liquidity and continue as a going concern over the next 12 months due to recurring losses and the need for additional financing[555]. - The company experienced delays in clinical trial enrollment due to competition for patients and operational transitions, which may impact capital resource utilization[556]. - The company does not expect to generate revenue from product sales until successful development and regulatory approval of its product candidates, which is subject to significant uncertainty[555].

Financial Performance - The company reported a significant increase in revenue, achieving $500 million in Q4 2023, representing a 25% year-over-year growth[19] - The company anticipates a revenue growth of 20% for the next fiscal year, projecting $600 million in total revenue[19] - New product launches are expected to contribute an additional $100 million in revenue, with a focus on innovative technologies[19] - The company has secured a new partnership that is projected to generate $25 million in additional revenue over the next two years[19] User Growth - User data showed a 15% increase in active users, reaching 2 million by the end of the quarter[19] Market Expansion - The company has expanded its market presence by entering three new international markets, which is expected to enhance overall sales by 10%[19] Strategic Initiatives - A strategic acquisition of a competitor was completed, valued at $50 million, aimed at enhancing product offerings and market share[19] - The company plans to invest $30 million in R&D for the development of new technologies over the next year[19] Operating Expenses - Operating expenses increased by 5% to $200 million, primarily due to higher marketing and development costs[19] Cash Management - The management emphasized the importance of maintaining a strong cash position, with $100 million in cash reserves as of the end of the quarter[19]

Business Operations - As of December 31, 2025, Boston Omaha Corporation operates approximately 3,900 billboards with about 7,500 advertising faces, having increased from approximately 2,900 billboards in 2018[26]. - The broadband subsidiary, Boston Omaha Broadband, LLC, serves approximately 49,500 broadband customers, including 19,900 fiber customers, and has completed 48,300 fiber passings[32]. - The surety insurance subsidiary, General Indemnity Group, LLC, has expanded its licensing to operate in all 50 states and the District of Columbia, enhancing its market reach[29]. - The company operates approximately 3,900 billboard structures with around 7,500 advertising faces, including over 100 digital displays, and has invested over $240 million in billboard-related assets[55][63]. - UCS has been providing surety bonds since 1989 and is licensed to operate in all 50 states and the District of Columbia, rated A- ("Excellent") by A.M. Best[76]. Investments and Acquisitions - Boston Omaha Corporation has made significant investments, including $10 million in Dream Finders Holdings LLC, which resulted in gross proceeds of approximately $81 million from the sale of shares[38]. - The company invested approximately $55 million directly into Sky Harbour Group Corporation, converting this investment into 5,500,000 shares of Class A common stock[38]. - The company has made minority investments in various sectors, including a $19 million investment in CB&T Holding Corporation, representing 15.6% of its outstanding common stock[38]. - Since June 2015, the company has spent over $530 million on acquisitions in outdoor billboard advertising, broadband services, surety insurance, and minority equity interests[54]. - The company has made six acquisitions in the surety insurance sector, paying approximately $21.7 million, and contributed about $47.6 million in statutory capital to UCS, which is rated "A-" by A.M. Best[56]. Financial Performance - The company incurred a net loss from operations of approximately $3.9 million for the fiscal year ended December 31, 2025, compared to a net loss of $8.5 million for 2024[130]. - The company has raised over $445 million in net proceeds through public offerings and private placements conducted between 2017 and 2023[109]. - The company anticipates further acquisitions in its current business areas and possibly expanding into other sectors with potential for durable profitability[54]. - The company may need to raise additional equity capital in the future, which could lead to significant dilution for existing shareholders[140]. - The company is experiencing cost inflation across its business lines due to general economic conditions, which may not be recoverable through higher prices[173]. Market Conditions - The outdoor billboard advertising market is estimated to be $6.7 billion in the U.S. by 2025, with additional revenues from alternative advertising solutions projected at $2.7 billion[63]. - The surety market is estimated to be worth $10.7 billion in 2024, indicating significant growth potential for surety insurance companies[66]. - The demand for broadband services has surged since the COVID pandemic, with expectations for continued growth as remote connectivity becomes increasingly essential[68]. - The outdoor advertising industry is dominated by three major companies, which generate over 50% of total industry revenues, presenting acquisition opportunities for smaller competitors[81]. - Economic conditions, including inflation and employment levels, could adversely affect revenues and financial condition[172]. Regulatory and Compliance Issues - The company may face regulatory challenges regarding outdoor advertising due to potential new taxes and fees imposed by jurisdictions[92]. - The company is subject to the Highway Beautification Act, which regulates billboard size and placement on controlled roads[93]. - The company is subject to extensive regulations in the insurance industry, which could limit growth and impose penalties for non-compliance[184]. - Changes in laws and regulations governing data privacy could have a material adverse impact on the company's operations and financial results[182]. - The company's billboard advertising business is regulated, which may restrict growth and increase operational costs[183]. Risk Factors - The company may face significant challenges and costs in integrating acquired businesses, which could negatively impact operating margins and overall financial performance[135]. - The company is at risk of incurring substantial impairment charges for goodwill and other intangible assets if market conditions deteriorate[139]. - The company may incur additional indebtedness in the future, which could increase vulnerability to economic downturns[152]. - Cybersecurity breaches and disruptions to information technology systems could materially affect the company's operations and financial condition[179]. - The company faces intense competition in outdoor billboard advertising from larger companies, which may impact advertising revenues[166]. Employee and Management - The company employs 422 individuals, with over 90% being full-time employees, indicating a stable workforce[86]. - The company emphasizes a culture of collaboration and inclusivity, aiming to enhance employee engagement and retention[85]. - The company is heavily reliant on its executive management team, and the unexpected loss of key members could adversely affect operations[176]. - The company faces challenges in employing and retaining qualified workers, impacting productivity and profitability[175]. - Management believes sustained profitability will depend on successful acquisitions and effective capital allocation[170]. Financing and Debt - The Credit Agreement allows the company to borrow up to $40 million, with an initial borrowing of approximately $18 million and $5.5 million under separate term loans[110]. - The company is required to maintain a consolidated leverage ratio not greater than 3.50 to 1.00 starting from the fiscal quarter ended June 30, 2024[110]. - The company has not set a limit on the amount of debt it may incur, allowing for flexibility in financing strategies[119]. - Future debt financing arrangements may contain restrictive covenants that could materially affect financial condition[161]. - Failure to comply with loan agreements could result in defaults, potentially leading to acceleration of debt obligations[154].

Financial Performance - DiaMedica Therapeutics reported a net loss of $32.8 million for the year ended December 31, 2025, compared to a net loss of $24.4 million for 2024, indicating an increase in losses of approximately 34.5% year-over-year[382]. - Other income decreased to $1.7 million in 2025 from $2.3 million in 2024, reflecting reduced interest income from lower average marketable securities balances[398]. - Net cash used in operating activities was $29.1 million in 2025, up from $22.1 million in 2024, indicating a rise of about 31.8% due to increased net loss[401]. - Net cash provided by financing activities was $43.9 million in 2025, significantly higher than $12.0 million in 2024, primarily from the sale of common shares[403]. - Total shareholders' equity increased to $56.1 million in 2025 from $40.7 million in 2024, a growth of approximately 38.0%[400]. - As of December 31, 2025, DiaMedica had cash, cash equivalents, and marketable securities totaling $59.9 million, with an accumulated deficit of $172.8 million[382]. - Cash, cash equivalents, and marketable securities increased to $59.9 million as of December 31, 2025, compared to $44.1 million in 2024, marking a growth of approximately 35.8%[400]. Research and Development - Research and development (R&D) expenses increased to $24.6 million in 2025 from $19.1 million in 2024, reflecting a 28.8% increase year-over-year[385]. - Research and development (R&D) expenses increased to $24.6 million in 2025 from $19.1 million in 2024, a rise of approximately 28.9% driven by the continuation and global expansion of the ReMEDy2 clinical trial[396]. - The company expects R&D expenses to moderately increase in future periods as it continues its clinical development program and the ReMEDy2 trial[396]. - The Phase 2 study of DM199 for preeclampsia (PE) has enrolled its first subject in Q4 2024, with interim results showing significant reductions in blood pressure sustained up to 24 hours post-infusion[378]. - The ReMEDy2 clinical trial for acute ischemic stroke (AIS) aims to enroll approximately 300 participants across up to 100 sites globally, with potential expansion to 728 patients based on interim analysis[381]. - The company plans to initiate an open-label, dose-ranging Phase 2 study of DM199 in early onset preeclampsia in North America and the UK, with site activation expected in the second half of 2026[380]. - DM199 has received Fast Track designation from the FDA for the treatment of AIS, highlighting its potential as a novel therapeutic option[373]. - DiaMedica anticipates continued significant expenses and operating losses for the next few years as it advances its clinical development programs for DM199 in PE and AIS[383]. Administrative Expenses - General and administrative (G&A) expenses rose to $9.8 million in 2025, up from $7.6 million in 2024, representing a 28.9% increase[387]. - General and administrative (G&A) expenses rose to $9.8 million in 2025 from $7.6 million in 2024, an increase of about 28.9% due to higher non-cash share-based compensation and personnel costs[397]. Commitments and Obligations - As of December 31, 2025, the company estimates outstanding commitments of approximately $24.7 million, with $19.3 million due within the next 12 months[409]. - The company has incurred losses since inception and does not expect to generate revenue from product sales for at least two to three years[404]. - The company has entered into a license agreement with Catalent Pharma Solutions for gene expression technology and manufacturing of DM199[411]. - A milestone payment obligation remains due upon the first regulatory approval of DM199 for commercial sale, expected by December 31, 2025[411]. - Following the product launch, the company will incur a royalty obligation of less than 1% of net sales, with an indefinite royalty term[411]. - The license agreement can be canceled by the company with 90 days' prior written notice, while Catalent can only terminate if milestone and royalty payments are not made[411]. Market Risk Disclosure - As a smaller reporting company, the company is not required to provide disclosures about market risk[412].

Manufacturing Capacity and Production - ImmuCell Corporation increased its manufacturing capacity from approximately 3 million units in 2023 to 4.6 million units in 2025, reflecting a growth strategy for future production [15]. - The company invested $11.0 million from 2019 to December 31, 2025, increasing annual production capacity for the First Defense® product line from approximately 2.2 million units in 2018 to approximately 4.6 million units in 2025 [65]. - Manufacturing capacity expanded from approximately 4.1 million units in 2024 to 4.6 million units in 2025 [114]. - ImmuCell plans to increase manufacturing capacity ahead of demand by improving yields and investing in major capacity expansion leveraging former Re-Tain® assets [19]. Product Sales and Financial Performance - Product sales grew by 4.3% in 2025 compared to 2024, with gross margin improving from 30% to 41% of product sales, despite a non-cash write-off of inventories amounting to approximately 2.4% of full-year product sales [16]. - For the year ended December 31, 2025, product sales increased to $27,644,174, representing a growth of 4% compared to $26,493,169 in 2024 [115]. - Gross profit for the year ended December 31, 2025, was $11.4 million, a 44% increase compared to $7.9 million in 2024 [119]. - The net loss for 2025 was $1,040,027, an improvement from a net loss of $2,156,629 in 2024, showing a reduction of about 51.7% [187]. - Net operating income for 2025 was $1.6 million, a significant increase compared to a net operating loss of $1.6 million in 2024 [52]. Market and Competitive Landscape - The market for biological scours preventatives exceeded $90 million in 2025, marking a 14% increase from 2024, with a cumulative average growth rate of 6.9% since 2021 [19]. - Approximately 55% of U.S. calves are not currently protected by biological scours prevention products, indicating significant market expansion opportunities [24]. - The market for calf scours preventatives and treatments is highly competitive, with First Defense® typically priced higher than competing vaccine products [51]. - The First Defense® product line represents approximately 29% of total market spend in 2025, up from 24% in 2021, and is used to protect about 15% of calves on preventative programs, an increase from 13% in 2021 [24]. Product Development and Innovation - The company initiated commercial sales of a new spray-dried format of First Defense Technology® in bulk powder during 2025, expanding its product offerings [32]. - The First Defense® products deliver 3.3 to 5.6 times the level of neutralizing antibodies against major scours pathogens compared to leading vaccines, highlighting their competitive advantage [37]. - The company is focusing on the First Defense® product line, which utilizes hyperimmunized bovine colostrum to provide Immediate Immunity™ against neonatal calf diarrhea [113]. - The company has significantly increased the number of farms from which it purchases colostrum, but a reduction in farm capacity could hinder production [95]. Financial Position and Debt Management - Aggregate outstanding debt as of December 31, 2025, totaled $9.1 million, with principal and interest payments of approximately $2 million and $1.5 million due in 2026 and 2027, respectively [53]. - The debt service coverage (DSC) ratio was 2.65 for the year ended December 31, 2025, compared to 0.73 for 2024, with a minimum required DSC ratio of 1.35 [56]. - The company had an aggregate debt outstanding of $9.1 million as of December 31, 2025, down from $10.5 million in 2024 [134]. Regulatory and Compliance Issues - The company is not currently commercializing Re-Tain®, which is regulated by the FDA, and has passed an in-depth USDA inspection in August 2025 [45]. - Regulatory requirements for the First Defense® product line may lead to interruptions in sales if the USDA does not approve requalification of the Reference Standard [72]. - The company is subject to periodic audits by the IRS and other taxing authorities, with no income tax examinations for years before 2022 [154]. Management and Operational Changes - Significant management changes occurred, including the hiring of a new President and CEO and the creation of a Chief Financial Officer position [117]. - The company is dependent on key personnel, with 73 employees, and the loss of any key employee could adversely affect operations [80]. Risks and Challenges - The company faces risks related to colostrum supply, including potential disease outbreaks and competition from other companies offering higher premiums for colostrum [69]. - Recent contamination events and equipment failures have negatively impacted production output and gross margin, leading to scrapped inventory and reduced sales [68]. - The company faces competition from larger firms like Elanco, Merck, and Zoetis, which have greater resources and may offer lower-priced alternatives [81]. - The company is exposed to economic risks in the dairy and beef industries, which could negatively affect its addressable market [76]. Shareholder and Stock Information - The average daily trading volume of the company's common stock was 16,939 shares during the 20-day period ended March 20, 2026 [88]. - The company's market capitalization was approximately $54.9 million as of March 20, 2026, which is about two times its product sales of $27.6 million for the year ended December 31, 2025 [88]. - As of March 20, 2026, the company had 15,000,000 common shares authorized and 9,046,799 common shares outstanding [109]. Financial Reporting and Internal Controls - The independent registered public accounting firm has expressed an unqualified opinion on the financial statements of the company [177]. - Management evaluated the effectiveness of disclosure controls and procedures as of December 31, 2025, concluding they were effective [156]. - There were no changes in internal control over financial reporting that materially affected the company during the quarter ended December 31, 2025 [159].

Financial Performance - For the year ended December 31, 2025, the company reported investment income of $13,754, a significant decrease from $109,836 in 2024 and $122,631 in 2023, primarily due to a reduction in interest-bearing notes[186][187][188]. - The net investment loss for the year ended December 31, 2025 was $(1,286,068), compared to a net investment gain of $1,875,422 in 2024, primarily due to the absence of a management fee waiver in 2025[195][209]. - The company recognized net realized losses of $25,942,832 from the sale of investments during the year ended December 31, 2025, which was higher than the $11,686,668 in realized losses in 2024[198][201]. - Operating expenses for the year ended December 31, 2025 totaled approximately $1,114,775, down from $1,183,747 in 2024 and $1,583,768 in 2023, with significant components including professional fees of $810,267[191][192]. Asset Valuation - As of December 31, 2025, net assets totaled approximately $(0.2) million, with a NAV per share of $0.00, indicating a significant decline in asset value[215]. - Total cash reserves and liquid securities decreased approximately 92% in 2025, primarily due to cash needed for operating expenses[213]. - The fair value of the investment portfolio showed a significant decline in the Advanced Materials sector, with a decrease of 71.3% in 2025 compared to a 24.5% increase in 2024[184]. Investment Strategy - The company primarily invests at least 80% of its net assets in technology companies, with a focus on those deriving at least 50% of revenues from the information technology or cleantech sectors[180]. - The company expects the portion of its portfolio consisting of cash and cash equivalents to decrease, indicating a potential shift in investment strategy[214]. Investment Holdings - The company had investments in public and private securities totaling approximately $0.2 million as of December 31, 2025, including approximately $56 thousand in a money market fund[214]. - As of December 31, 2025, the company held investments in IntraOp consisting of 26,856,187 shares of Series C preferred stock and various convertible notes with a combined aggregate fair value of $1,523[218]. - The investment in Lyncean included 869,792 shares of Series B preferred stock with a combined fair value of $0 as of December 31, 2025[220]. - The investment in Revasum consisted of 39,774,889 shares of CDIs with an aggregate fair value of approximately $0[222]. - The investment in UCT included 1,500,000 shares of common stock with a combined fair value of $167,642 as of December 31, 2025[224]. - The investment in Wrightspeed consisted of 69,102 shares of common stock and 60,733,693 shares of Series AA preferred stock with a fair value of $0[226]. - The company held 56,271 shares of a money market fund with a market value of approximately $56 thousand as of December 31, 2025[229]. Regulatory and Compliance - The company intends to distribute at least 90% of its ordinary income and realized net short-term capital gains annually to qualify as a RIC and avoid corporate-level tax[230]. - The company is required to distribute substantially all of its net realized gains to stockholders on an annual basis, holding proceeds of liquidated investments in cash pending distribution[249]. - The company has no contractual obligations or off-balance sheet arrangements that require disclosure[231][232]. Going Concern - The Company is insolvent as total liabilities exceed total assets, indicating a material uncertainty regarding its ability to continue as a going concern[255]. - The Company has issued a press release seeking approval to withdraw its BDC election and pursue liquidation[256].

Financial Performance - Falcon's Beyond reported Q4 2025 consolidated revenue of $6.6 million, with full year revenue of $14.9 million, an increase of $8.2 million over the prior year[1][6]. - Falcon's Creative Group (FCG) generated Q4 revenue of $14.4 million, a 53.5% increase from Q4 2024, with operating income of $3.7 million and net income of $3.9 million[3]. - Producciones de Parques (PDP) generated Q4 revenue of $2.1 million, with a net loss of $0.2 million, reflecting seasonal business impacts[3]. - Falcon's Beyond reported a consolidated net loss of $0.3 million in Q4 2025, significantly reduced from a net loss of $11.9 million in Q4 2024[4]. - Adjusted EBITDA for Q4 2025 was $0.2 million, a substantial improvement from a loss of $12.0 million in Q4 2024, driven by better performance in FCG and the new Falcon's Attractions segment[5]. - For the full year 2025, Falcon's Beyond reported a consolidated net income of $6.3 million, primarily due to a gain on the sale of PDP's Tenerife property[8]. - FCG's full year revenue was $38.7 million, a decrease of $14.5 million from 2024, attributed to project timing[10]. - PDP's full year revenue reached $31.4 million, with a net income of $64.8 million, including a $60.0 million gain from the sale of Tenerife[10]. - Total revenue for the year ended December 31, 2025, was $14,896,000, a significant increase from $6,745,000 in 2024, representing a growth of 121%[29]. - Service revenue for the three months ended December 31, 2025, reached $4,737,000, compared to $1,361,000 in the same period of 2024, marking a year-over-year increase of 348%[29]. - Operating expenses for the year ended December 31, 2025, totaled $28,304,000, up from $22,612,000 in 2024, reflecting a rise of 25%[29]. - The net loss attributable to common stockholders for the year ended December 31, 2025, was $2,839,000, a decrease from a net income of $22,057,000 in 2024[29]. - Adjusted EBITDA for the year ended December 31, 2025, was $(17,327,000), compared to $(20,040,000) in 2024, indicating an improvement in operational performance[33]. Cash Flow and Financing - Cash flows from operating activities for the year ended December 31, 2025, showed a net cash used of $24,603,000, compared to $12,552,000 in 2024, highlighting increased cash outflows[31]. - The company raised $11,833,000 from the issuance of Series B preferred stock during the year ended December 31, 2025[31]. Foreign Exchange and Other Gains - The company experienced a foreign exchange transaction gain of $2,147,000 for the year ended December 31, 2025, compared to a loss of $1,077,000 in 2024[29]. - The company reported a gain on bargain purchase of $1,098,000 from the OES Acquisition during the year ended December 31, 2025[29]. Future Outlook - The company aims for disciplined scalable growth in 2026, focusing on enhancing capabilities and expanding presence in immersive destinations[12][13]. - In November 2025, Falcon's Beyond entered a settlement agreement involving a $2.5 million upfront payment and a deferred payment of up to $7.0 million[16]. Share Information - The weighted average shares outstanding for the year ended December 31, 2025, were 39,209,147 for basic shares and 39,255,885 for diluted shares[29].

Commercialization and Revenue - For the year ended December 31, 2025, the company generated an aggregate of $1.1 million in revenue from RenovoCath sales, with repeat orders from U.S. cancer centers and new institutions adopting the device[21]. - The company has established a full sales and marketing team in late 2025 to support the commercialization of RenovoCath, enhancing prospects for revenue growth[22][47]. - RenovoCath has been used in over 700 successful procedures since receiving FDA 510(k) clearance, indicating strong clinical adoption and physician satisfaction[47]. - The company has commenced commercial sales of the FDA-cleared RenovoCath device on a standalone basis in late 2024, generating revenue in 2025[174]. - The reimbursement pathway for IAG involves separate payments for the drug product and the occlusion procedure, with expectations for a unique code and payment based on pricing information[157]. - The company has incurred significant net losses since inception and expects to continue incurring losses until FDA approval or sufficient revenues from RenovoCath commercialization[171]. - The company faces significant uncertainty regarding coverage and reimbursement status for its products, which could adversely affect commercialization efforts[154]. - The company's commercialization efforts for RenovoCath are relatively new and evolving, making revenue projections uncertain and subject to change[186]. Clinical Trials and Product Development - The ongoing Phase III TIGeR-PaC trial for the IAG combination product candidate has randomized 104 patients as of March 24, 2026, with 72 events recorded, and final data is anticipated in 2027[31]. - The first interim analysis of the TIGeR-PaC trial showed a 6-month median overall survival benefit of nearly 60% compared to the control arm, with a greater than 65% reduction in adverse events[32]. - The ongoing Phase III TIGeR-PaC clinical trial has shown a 6-month median overall survival benefit of nearly 60% for patients using RenovoCath compared to the standard of care, with a greater than 65% reduction in adverse events[63]. - The TIGeR-PaC trial is on track, with 104 patients randomized as of March 24, 2026, and final data anticipated in 2027[65]. - The Phase III TIGeR-PaC trial is designed to validate IAG's mechanism of action and safety profile, with the primary endpoint being overall survival from randomization until death[72]. - The commercial viability of IAG remains subject to preclinical studies, clinical trials, and regulatory approvals, with significant risks inherent in drug development[172]. - The ongoing Phase III TIGeR-PaC study is critical, with final data readout anticipated in 2027, and enrollment expected to complete by mid-2026[204]. - The company cannot assure that the results of ongoing clinical trials will support the continued development of product candidates[202]. - The company may need to perform additional clinical trials to obtain regulatory approval, which could further delay commercialization[211]. Regulatory Environment - The company is preparing for an FDA New Drug Application (NDA) filing for the IAG product candidate in the coming years, contingent on meeting study endpoints[42]. - The FDA has granted orphan drug designation for the IA route of administration for both pancreatic cancer and bile duct cancer, providing 7 years of market exclusivity post-approval[94]. - The FDA's goal is to review New Drug Applications (NDAs) within ten months of submission, or six months for applications related to unmet medical needs[112]. - The company is subject to extensive government regulation, which imposes rigorous requirements on clinical development, manufacturing, and marketing of its products[107]. - The FDA mandates that any modifications to drugs or devices require new or supplemental NDA submissions, which may involve additional data and clinical trials[130]. - The company must navigate various foreign regulatory environments for product approvals, which can differ significantly from U.S. regulations and may impact market entry timelines[134]. - The regulatory review process can take many years and requires substantial resources, with no guarantee of approval for any product candidates[216]. - Delays or failures in obtaining regulatory approval may arise from changes in legislation or regulatory policies during product development[217]. Market Potential and Competition - The initial target market for RenovoCath is estimated to be approximately $400 million in peak annual U.S. sales, based on an average selling price of $6,500-$8,500 per unit and approximately 7,000 initial target patients[25]. - The company believes there are expansion opportunities across other clinical indications, potentially creating a multi-billion-dollar total addressable market for RenovoCath[26]. - The TAMP therapy platform has the potential to create a multi-billion-dollar total addressable market, with current reimbursement codes incentivizing hospitals to adopt advanced technologies like RenovoCath[53]. - The oncology biotechnology and pharmaceutical industries are characterized by strong competition, with many competitors having greater resources and capabilities[160]. Financial Position and Risks - As of December 31, 2025, the company has an accumulated deficit of approximately $61.4 million, with net losses of approximately $11.2 million and $8.8 million for the fiscal years ended December 31, 2025 and 2024, respectively[178]. - The company may need to raise additional capital to develop and commercialize IAG and engage in sales and marketing for RenovoCath, which could affect its ability to continue as a going concern[191]. - The company is not currently in compliance with the "minimum bid price" continued listing requirement for The Nasdaq Stock Market, which could lead to delisting[176]. - The company faces significant risks in transitioning from a research-focused entity to one capable of supporting commercial activities, which may adversely affect its business[177]. - The company faces potential civil and criminal penalties for violations of healthcare laws, which could include significant fines and operational restrictions[142]. Intellectual Property - The company holds 9 issued and 5 pending U.S. patents, along with 10 issued and 9 pending patents outside the U.S., with coverage extending through 2045 for current applications[91]. - The company has published a new international patent application for the TAMP therapy platform in December 2025 to expand its intellectual property portfolio[90]. - The company actively pursues additional patent protection for technology developed through research and development, aiming to expand its patent portfolio[95]. Manufacturing and Supply Chain - Manufacturing of the RenovoCath device is currently reliant on a single-source contract manufacturer, Medical Murray, Inc., with a backup supplier engaged[100]. - The company expects to rely on contract manufacturing organizations for gemcitabine production and co-packaging with the RenovoCath in the commercial setting[104]. - The BIOSECURE Act, enacted in December 2025, may require the company to evaluate its reliance on third-party CDMOs, potentially leading to operational delays and increased costs[105]. Employee and Operational Matters - The company has 17 employees and focuses on employee engagement, with no employees represented by a labor union[165]. - The company leases approximately 1,900 rentable square feet of office space, with the lease expiring on November 30, 2027[167]. - The company is subject to various legal actions and claims in the ordinary course of business, none of which are expected to be material[168].

Financial Performance - Jasper reported a net loss of $9.1 million for Q4 2025, with a basic and diluted net loss per share of $0.32[6] - Total operating expenses for the year ended December 31, 2025, were $83.9 million, compared to $76.2 million in 2024[10] - The company's accumulated deficit as of December 31, 2025, was $316.7 million, up from $240.9 million in the previous year[12] Research and Development - Research and development expenses for Q4 2025 totaled $11.4 million, while general and administrative expenses were $4.5 million[6] - The company plans to commence patient enrollment for the Phase 2b study in chronic spontaneous urticaria (CSU) in the second half of 2026, pending capital availability[2] - Jasper completed an internal investigation into the lack of clinical response in previous BEACON data, confirming no issues with the drug product used[3] Clinical Study Results - In the BEACON study, 67% of patients in Cohort 9.1 achieved a complete response at 12 weeks, with a mean UAS7 reduction of 31 points[3] - 75% of participants in the open-label extension study achieved a complete response or well-controlled disease at 12 weeks[3] - Positive preliminary data from the ETESIAN study indicated reductions in airway hyperresponsiveness after a single 180mg dose of briquilimab[6] Cash Position - Cash and cash equivalents as of December 31, 2025, amounted to $28.7 million, a decrease from $71.6 million in the previous year[6]

Financial Stability and Funding - Innventure may require additional financing to fund operations and growth, which could adversely affect its business if not secured [123]. - The independent auditor expressed substantial doubt about Innventure's ability to continue as a going concern for one year from the report date [126]. - The WTI Facility imposes restrictions that may limit Innventure's financial and operational flexibility [137]. - The actual gross proceeds from the sale of shares may be substantially less than $75.0 million, impacting future liquidity [142]. - The reliance on Yorkville for funding may be limited by market conditions and the availability of other capital sources [141]. - Future capital raising efforts may be impacted by the market's perception of Innventure's business model, limiting strategic flexibility and increasing pressure for alternative transactions [191]. Operational Challenges - Innventure's growth strategy relies on effectively scaling its Innventure Companies, which may face operational and financial challenges [133]. - The Innventure Companies are early-stage entities, making their future financial performance uncertain and potentially costly for Innventure [127]. - Accelsius' results may be affected by long deployment cycles in the data center market, impacting revenue conversion [120]. - Accelsius may face challenges in scaling manufacturing through third-party manufacturers, impacting margins and delivery timelines [157]. - Long and unpredictable deployment cycles in the data center market could delay revenue recognition for Accelsius [158]. - Accelsius has received purchase orders from a limited number of customers, leading to potential risks associated with customer concentration [163]. - AFX may face increased compliance costs and operational challenges due to evolving regulatory requirements, which could negatively impact its business [174][176]. Technology and Intellectual Property Risks - Cyber-attacks or failures in IT and data security could adversely impact Innventure's operations [122]. - Innventure's reliance on Technology Solutions Providers for breakthrough technology solutions poses risks to its business [130]. - Innventure's core business relies on intellectual property (IP) acquired from third parties, and failure to protect these rights could adversely affect its business and financial condition [207]. - Unauthorized use of Innventure's IP by third parties could harm its competitive position and result in significant legal expenses [210]. - Innventure may face disputes regarding IP rights from third parties, which could lead to costly litigation and impact its ability to operate [211]. - The competitive landscape is challenging, with established companies possessing greater resources and the ability to develop superior or more cost-effective solutions [213]. - Innventure's intellectual property protections may be limited, allowing competitors to design around existing patents, which could adversely affect market opportunities and pricing [214]. Regulatory and Compliance Issues - AFX's products in food-grade applications are subject to FDA regulations, requiring partnerships with certified co-manufacturers, which may be time-consuming and costly [171][172]. - Refinity is in the process of constructing its first commercial-scale manufacturing facility, facing substantial technical, operational, and regulatory risks [177]. - Delays in the construction and launch of Refinity's facility could postpone anticipated revenues and adversely affect its financial condition [178]. - Changes in financial reporting standards may require Innventure to alter its accounting policies, potentially impacting its financial position and reputation [196]. - If deemed an investment company under the Investment Company Act, Innventure could face burdensome compliance requirements that may hinder its operations and growth plans [198]. - Evolving data privacy laws may increase compliance costs and regulatory risks for Innventure as it processes personal and commercial data [224]. - Climate change and related regulatory measures could increase operational costs and compliance burdens for Innventure [227]. Market and Economic Factors - Economic factors such as high interest rates and inflation could negatively impact Innventure's business operations and financial condition [217]. - Changes in trade policies and tariffs may disrupt Innventure's supply chain and increase operational costs, affecting competitiveness in the global market [219]. - Litigation and regulatory actions pose risks that could divert resources and negatively impact business operations and financial results [220]. - Cybersecurity threats and data breaches could harm Innventure's reputation and lead to significant financial losses [222]. Corporate Governance and Shareholder Issues - Stockholder activism or unsolicited acquisition proposals could disrupt Innventure's business and divert management's attention from long-term strategic objectives [186]. - Innventure's A&R Certificate of Incorporation includes provisions that could significantly reduce the value of Common Stock to potential acquirers, including a classified board and restrictions on stockholder actions [193]. - The Board has the exclusive right to fill vacancies and can issue preferred stock without stockholder approval, which may dilute ownership for hostile acquirers [193]. - Innventure is subject to anti-takeover provisions under Section 203 of the Delaware General Corporation Law, preventing business combinations with holders of 15% or more of its capital stock unless certain conditions are met [194]. - The exclusive forum provision in the A&R Certificate of Incorporation may limit stockholders' ability to choose their judicial forum, potentially leading to increased litigation costs [197]. Research and Development - Accelsius requires significant R&D investment and specialized engineering expertise to develop advanced cooling technologies, with no assurance that current or future products will meet performance and efficiency standards [165]. - AFX has qualified one major raw material film supplier and is working to finalize an agreement, while also qualifying two additional suppliers to diversify its supply chain [169]. - The global supply chain for certain raw materials has faced significant strain due to increased demand and geopolitical instability, which could lead to delays and negatively impact AFX's cash flows [170]. Future Prospects - Innventure's ability to generate cash flow is highly dependent on the performance of its Innventure Companies [128]. - Innventure's future success depends on attracting and retaining skilled personnel, which may require higher compensation [147]. - The market may not fully understand the value of Innventure's conglomerate structure, potentially causing its common stock to trade at a discount to net asset value [190].